Trips Agreement and Access to Medicine

The World Trade Organization`s (WTO) Agreement on Trade-Related Aspects of Intellectual Property Rights (TRIPS) was signed in 1994 to ensure that intellectual property rights (IPRs) were enforced and protected globally. However, the agreement`s implementation has had a significant impact on access to medicine in developing countries.

TRIPS obliges its signatories to enforce IPRs on pharmaceutical products, including patents, trademarks, and copyrights, which significantly increases the cost of medicines. The agreement also prevents the production and distribution of cheaper, generic versions of patented medicines, which makes life-saving drugs unaffordable for millions of people in the developing world.

The lack of access to affordable medicines is a severe public health issue, particularly in developing countries, where the prevalence of diseases such as HIV/AIDS, malaria, and tuberculosis is high. The high costs of patented medicines mean that patients and health systems cannot afford to purchase and distribute the drugs needed to combat these diseases.

To address these concerns, the WTO issued the Doha Declaration on TRIPS and Public Health in 2001, which recognized the need for access to medicine as a public health matter. The declaration affirmed that the TRIPS agreement should not prevent member states from taking steps to protect public health and promote access to medicines.

The Doha Declaration also allowed developing countries to issue compulsory licenses, which permit the production of generic versions of patented medicines without the consent of the patent holder. This provision allows developing countries to produce and distribute affordable medicine to meet their population`s health needs.

Since the Doha Declaration, several developing countries, including Brazil, India, and Thailand, have issued compulsory licenses to produce essential medicines. The move has been critical in providing affordable medicines to their populations.

However, developed countries and pharmaceutical companies have criticized the use of compulsory licenses, arguing that it violates the spirit of the TRIPS agreement and undermines innovation in the pharmaceutical industry.

In conclusion, the TRIPS agreement has had a significant impact on access to medicine in developing countries. While the Doha Declaration provided some relief, the issue of access to affordable medicine continues to be a public health concern. It is essential to balance the protection of IPRs with the need to ensure access to essential medicines for all, particularly those living in poor countries.

Scroll to Top